Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)

The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026LONDON and PHILADELPHIA, (GLOBE NEWSWIRE) ...
Business Insider

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

LONDON and PHILADELPHIA, Oct. 25, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a ...
Eagle-Tribune

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 ...

LONDON and PHILADELPHIA, Oct. 25, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a ...
Fox2Now St. Louis

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease ...
Pharmabiz

Avacta Therapeutics receives US FDA clearance of investigational new drug application for FAP-Exd (AVA6103)

Avacta Therapeutics, a clinical stage biopharmaceutical company developing pre|CISION, a tumour-activated oncology delivery platform, has announced the US Food and Drug Administration (FDA) clearance ...
ksn.com

Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting

Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival (PFS) data to ...